CFA
ORKA

Camarda Financial Advisors’s Oruka Therapeutics ORKA Stock Holding History

Camarda Financial Advisors’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-1
Closed -$1K – 260
2016
Q2 		$1K Buy
+1
New +$740 ﹤0.01% 257

Other funds holding ORKA

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Camarda Financial Advisors's ORKA Position: Q3 2016 in Review

Camarda Financial Advisors sold out of Oruka Therapeutics (ORKA) in Q3 2016, closing a stake of 1 share — an estimated $1K sold.

Camarda Financial Advisors first reported a position in ORKA in Q2 2016 and held it in 1 quarter. The position peaked at $1K in Q2 2016. 17 funds tracked by Wall St. Rank hold ORKA as of Q3 2016.

  • Camarda Financial Advisors reported no remaining Oruka Therapeutics position as of Q3 2016 after selling out during the quarter.
  • Camarda Financial Advisors sold 1 Oruka Therapeutics share in Q3 2016, an estimated $1K.
  • Camarda Financial Advisors first reported a position in Oruka Therapeutics in Q2 2016 and held it in 1 quarter.
  • Camarda Financial Advisors's Oruka Therapeutics position peaked at $1K in Q2 2016.
  • 17 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q3 2016.

Based on Camarda Financial Advisors's 13F filing for Q3 2016, filed 10 Nov 2016.